MALDI 질량 분광화상 영상을 이용한 대사 프로파일링을 위한 샘플 준비

Executive Industry Relevance

MALDI MSI enables label-free spatial mapping of metabolites, supporting target validation and mechanistic de-risking in early discovery. The technique provides quantitative, visualization-ready data that aids in hypothesis testing and portfolio triage for metabolic pathways. Proper sample preparation ensures reproducibility and predictive confidence in downstream applications.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses through metabolite distribution mapping.
• Operational Value: Supports biological de-risking by visualizing metabolite enrichment in disease-relevant tissues.
• Predictive Value: Facilitates target confidence by linking metabolite signatures to developmental or pathological states.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems for downstream screening with spatial metabolite resolution.
• Operational Value: Ensures assay standardization through reproducible cryosectioning and matrix deposition protocols.
• Scalability: Enables platform reuse across tissue types and developmental stages for consistent compound evaluation.

Translational & Preclinical Research

• Translational Continuity: Connects discovery-phase metabolite profiling to preclinical validation via developmental stage comparisons.
• Biomarker Alignment: Supports identification of metabolites enriched in specific anatomical structures or disease conditions.
• Risk-Adjusted Decisions: Informs advancement choices by revealing spatially resolved metabolic phenotypes across models.

Pipeline & Workflow Integration

The method integrates into the discovery continuum from hypothesis testing to lead identification by providing spatially resolved metabolic data that informs target selection and validation.

• Discovery Biology: Supports pathway clarification and biological de-risking through metabolite ion heat maps across tissue compartments.
• Screening: Delivers assay readiness via standardized tissue sectioning and matrix application for reliable compound screening.
• Analytics: Generates quantitative mass discharge spectra at 100 Dalton intervals for comparative condition analysis.
• Translational Research: Enables continuity from neonatal to adult tissue metabolite profiling for developmental biomarker alignment.
• Enterprise Reuse: Establishes a reusable capability for metabolic profiling across disease models and therapeutic areas.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence through label-free metabolite detection and spatial distribution analysis.
• Operational Value: Standardization and reproducibility via controlled cryostat sectioning and matrix deposition.
• Strategic Value: Improved go/no-go decisions by reducing mechanistic ambiguity in metabolic pathway analysis.
• Portfolio Impact: Risk-adjusted prioritization via visualization of metabolite enrichment in disease-relevant models.

Implementation Considerations

• Requires expertise in cryostat operation, tissue handling, and MALDI-compatible slide preparation.
• Dependent on instrumentation including cryostat, matrix sprayer, and MALDI-MS imaging platform.
• Necessitates cross-team standardization for sample storage, sectioning thickness, and matrix application consistency.
• Involves adaptation considerations for varying tissue types and developmental stages in neuropathological models.
• Limited by sample degradation risks if dissection, storage, or sectioning protocols are not strictly followed.

Biopharma FAQs